Current advances in esophageal cancer proteomics

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1854, Issue 6, 2015, Pages 687-695

  Uemura, Norihisa ^a   Kondo, Tadashi ^b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Biomarker; Esophageal cancer; Molecular mechanism; Neoadjuvant therapy; Proteomics

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEOME; TUMOR MARKER; TUMOR PROTEIN;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESEARCH; CARCINOGENESIS; COOPERATION; DRUG TARGETING; EARLY DIAGNOSIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; GENOME; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MOLECULAR PATHOLOGY; NONHUMAN; ONCOLOGIST; OUTCOME ASSESSMENT; PATHOLOGIST; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEOMICS; REVIEW; SCIENTIST; TRANSLATION REGULATION; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; METABOLISM; PATHOLOGY; PROCEDURES;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM PROTEINS; PRECISION MEDICINE; PROTEOMICS;

EID: 84961287813     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2014.09.011     Document Type: Review

References (85)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J. Clin. 61 2011 69 90
2. T.W. Rice, V.W. Rusch, C. Apperson-Hansen, M.S. Allen, L.Q. Chen, J.G. Hunter, K.A. Kesler, S. Law, T.E. Lerut, C.E. Reed, J.A. Salo, W.J. Scott, S.G. Swisher, T.J. Watson, and E.H. Blackstone Worldwide esophageal cancer collaboration Dis. Esophagus 22 2009 1 8
3. Y. Shimizu, H. Tsukagoshi, M. Fujita, M. Hosokawa, M. Kato, and M. Asaka Long-term outcome after endoscopic mucosal resection in patients with esophageal squamous cell carcinoma invading the muscularis mucosae or deeper Gastrointest. Endosc. 56 2002 387 390
4. T.W. Rice, G. Zuccaro Jr., D.J. Adelstein, L.A. Rybicki, E.H. Blackstone, and J.R. Goldblum Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status Ann. Thorac. Surg. 65 1998 787 792
5. J.D. Urschel, and H. Vasan A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer Am. J. Surg. 185 2003 538 543
6. I.G. Kaklamanos, G.R. Walker, K. Ferry, D. Franceschi, and A.S. Livingstone Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomized clinical trials Ann. Surg. Oncol. 10 2003 754 761
7. R.A. Malthaner, R.K. Wong, R.B. Rumble, L. Zuraw, and C. Members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis BMC Med. 2 2004 35
8. F. Fiorica, D. Di Bona, F. Schepis, A. Licata, L. Shahied, A. Venturi, A.M. Falchi, A. Craxi, and C. Camma Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis Gut 53 2004 925 930
9. S.E. Greer, P.P. Goodney, J.E. Sutton, and J.D. Birkmeyer Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis Surgery 137 2005 172 177
10. V. Gebski, B. Burmeister, B.M. Smithers, K. Foo, J. Zalcberg, J. Simes, and G. Australasian Gastro-Intestinal Trials Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis Lancet Oncol. 8 2007 226 234
11. X.H. Xu, X.H. Peng, P. Yu, X.Y. Xu, E.H. Cai, P. Guo, and K. Li Neoadjuvant chemotherapy for resectable esophageal carcinoma: a meta-analysis of randomized clinical trials Asian Pac. J. Cancer Prev. 13 2012 103 110
12. N.P. Nguyen, S.P. Krafft, V. Vinh-Hung, P. Vos, F. Almeida, S. Jang, M. Ceizyk, A. Desai, R. Davis, R. Hamilton, H. Modarresifar, D. Abraham, and L. Smith-Raymond Feasibility of tomotherapy to reduce normal lung and cardiac toxicity for distal esophageal cancer compared to three-dimensional radiotherapy Radiother. Oncol. 101 2011 438 442
13. M. Tyers, and M. Mann From genomics to proteomics Nature 422 2003 193 197
14. G. Chen, T.G. Gharib, C.C. Huang, J.M. Taylor, D.E. Misek, S.L. Kardia, T.J. Giordano, M.D. Iannettoni, M.B. Orringer, S.M. Hanash, and D.G. Beer Discordant protein and mRNA expression in lung adenocarcinomas Mol. Cell. Proteomics 1 2002 304 313
15. S. Varambally, J. Yu, B. Laxman, D.R. Rhodes, R. Mehra, S.A. Tomlins, R.B. Shah, U. Chandran, F.A. Monzon, M.J. Becich, J.T. Wei, K.J. Pienta, D. Ghosh, M.A. Rubin, and A.M. Chinnaiyan Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression Cancer Cell 8 2005 393 406
16. S.P. Gygi, Y. Rochon, B.R. Franza, and R. Aebersold Correlation between protein and mRNA abundance in yeast Mol. Cell. Biol. 19 1999 1720 1730
17. R.E. Banks, M.J. Dunn, D.F. Hochstrasser, J.C. Sanchez, W. Blackstock, D.J. Pappin, and P.J. Selby Proteomics: new perspectives, new biomedical opportunities Lancet 356 2000 1749 1756
18. L. Smith, M.J. Lind, K.J. Welham, L. Cawkwell, and G. Cancer Biology Proteomics Cancer proteomics and its application to discovery of therapy response markers in human cancer Cancer 107 2006 232 241
19. F. Sabounchi-Schutt, J. Astrom, I. Olsson, A. Eklund, J. Grunewald, and B. Bjellqvist An immobiline DryStrip application method enabling high-capacity two-dimensional gel electrophoresis Electrophoresis 21 2000 3649 3656
20. M. Unlu, M.E. Morgan, and J.S. Minden Difference gel electrophoresis: a single gel method for detecting changes in protein extracts Electrophoresis 18 1997 2071 2077
21. R. Tonge, J. Shaw, B. Middleton, R. Rowlinson, S. Rayner, J. Young, F. Pognan, E. Hawkins, I. Currie, and M. Davison Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology Proteomics 1 2001 377 396
22. T. Kondo, M. Seike, Y. Mori, K. Fujii, T. Yamada, and S. Hirohashi Application of sensitive fluorescent dyes in linkage of laser microdissection and two-dimensional gel electrophoresis as a cancer proteomic study tool Proteomics 3 2003 1758 1766
23. N. Uemura, Y. Nakanishi, H. Kato, S. Saito, M. Nagino, S. Hirohashi, and T. Kondo Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics Int. J. Cancer 124 2009 2106 2115
24. N. Uemura, Y. Nakanishi, H. Kato, M. Nagino, S. Hirohashi, and T. Kondo Antibody-based proteomics for esophageal cancer: identification of proteins in the nuclear factor-kappaB pathway and mitotic checkpoint Cancer Sci. 100 2009 1612 1622
25. Y.J. Qi, W.X. Chao, and J.F. Chiu An overview of esophageal squamous cell carcinoma proteomics J. Proteome 75 2012 3129 3137
26. L.Y. Zhang, W.T. Ying, Y.S. Mao, H.Z. He, Y. Liu, H.X. Wang, F. Liu, K. Wang, D.C. Zhang, Y. Wang, M. Wu, X.H. Qian, and X.H. Zhao Loss of clusterin both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches World J. Gastroenterol. 9 2003 650 654
27. G. Zhou, H. Li, D. DeCamp, S. Chen, H. Shu, Y. Gong, M. Flaig, J.W. Gillespie, N. Hu, P.R. Taylor, M.R. Emmert-Buck, L.A. Liotta, E.F. Petricoin III, and Y. Zhao 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers Mol. Cell. Proteomics 1 2002 117 124
28. X. Chen, N. Li, S. Wang, J. Hong, M. Fang, J. Yousselfson, P. Yang, R.A. Newman, R.A. Lubet, and C.S. Yang Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and alpha-difluoromethylornithine on tumorigenesis in a rat surgical model Carcinogenesis 23 2002 2095 2102
29. C. Lepage, B. Rachet, V. Jooste, J. Faivre, and M.P. Coleman Continuing rapid increase in esophageal adenocarcinoma in England and Wales Am. J. Gastroenterol. 103 2008 2694 2699
30. H. Pohl, and H.G. Welch The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence J. Natl. Cancer Inst. 97 2005 142 146
31. R.P. Merkow, K.Y. Bilimoria, M.D. McCarter, W.B. Chow, C.Y. Ko, and D.J. Bentrem Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals Ann. Surg. Oncol. 19 2012 357 364
32. E. Bollschweiler, R. Metzger, U. Drebber, S. Baldus, D. Vallbohmer, M. Kocher, and A.H. Holscher Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis Ann. Oncol. 20 2009 231 238
33. A.B. Lopes, and R.B. Fagundes Esophageal squamous cell carcinoma - precursor lesions and early diagnosis World J. Gastrointest. Endosc. 4 2012 9 16
34. L.B. Gerson, P.W. Groeneveld, and G. Triadafilopoulos Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease Clin. Gastroenterol. Hepatol. 2 2004 868 879
35. E.L. Bird-Lieberman, and R.C. Fitzgerald Early diagnosis of oesophageal cancer Br. J. Cancer 101 2009 1 6
36. N.J. Fan, C.F. Gao, and X.L. Wang Tubulin beta chain, filamin A alpha isoform 1, and cytochrome b-c1 complex subunit 1 as serological diagnostic biomarkers of esophageal squamous cell carcinoma: a proteomics study OMICS J. Integr. Biol. 17 2013 215 223
37. W.L. Liu, G. Zhang, J.Y. Wang, J.Y. Cao, X.Z. Guo, L.H. Xu, M.Z. Li, L.B. Song, W.L. Huang, and M.S. Zeng Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma Biochem. Biophys. Res. Commun. 375 2008 440 445
38. Y. Fujita, T. Nakanishi, Y. Miyamoto, M. Hiramatsu, H. Mabuchi, A. Miyamoto, A. Shimizu, T. Takubo, and N. Tanigawa Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma Cancer Lett. 263 2008 280 290
39. Y. Mechref, A. Hussein, S. Bekesova, V. Pungpapong, M. Zhang, L.E. Dobrolecki, R.J. Hickey, Z.T. Hammoud, and M.V. Novotny Quantitative serum glycomics of esophageal adenocarcinoma and other esophageal disease onsets J. Proteome Res. 8 2009 2656 2666
40. S.S. Biere, M.I. van Berge Henegouwen, K.W. Maas, L. Bonavina, C. Rosman, J.R. Garcia, S.S. Gisbertz, J.H. Klinkenbijl, M.W. Hollmann, E.S. de Lange, H.J. Bonjer, D.L. van der Peet, and M.A. Cuesta Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial Lancet 379 2012 1887 1892
41. Y. Tachimori, Y. Nagai, N. Kanamori, N. Hokamura, and H. Igaki Pattern of lymph node metastases of esophageal squamous cell carcinoma based on the anatomical lymphatic drainage system Dis. Esophagus 24 2011 33 38
42. B.M. Stiles, F. Mirza, A. Coppolino, J.L. Port, P.C. Lee, S. Paul, and N.K. Altorki Clinical T2-T3N0M0 esophageal cancer: the risk of node positive disease Ann. Thorac. Surg. 92 2011 491 496 (discussion 496-498)
43. H. Hatakeyama, T. Kondo, K. Fujii, Y. Nakanishi, H. Kato, S. Fukuda, and S. Hirohashi Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer Proteomics 6 2006 6300 6316
44. L. Fu, Y.R. Qin, D. Xie, H.Y. Chow, S.M. Ngai, D.L. Kwong, Y. Li, and X.Y. Guan Identification of alpha-actinin 4 and 67 kDa laminin receptor as stage-specific markers in esophageal cancer via proteomic approaches Cancer 110 2007 2672 2681
45. J.G. Feng, Q. Liu, X. Qin, Y.H. Geng, S.T. Zheng, T. Liu, I. Sheyhidin, and X.M. Lu Clinicopathological pattern and Annexin A2 and Cdc42 status in patients presenting with differentiation and lymphnode metastasis of esophageal squamous cell carcinomas Mol. Biol. Rep. 39 2012 1267 1274
46. D. Berg, C. Wolff, R. Langer, T. Schuster, M. Feith, J. Slotta-Huspenina, K. Malinowsky, and K.F. Becker Discovery of new molecular subtypes in oesophageal adenocarcinoma PLoS One 6 2011 e23985
47. F. Sato, Y. Shimada, Z. Li, G. Watanabe, M. Maeda, and M. Imamura Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma Br. J. Surg. 88 2001 426 432
48. K. Almhanna, R. Shridhar, and K.L. Meredith Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care? Cancer Control 20 2013 89 96
49. N.S. Blencowe, A.G. McNair, C.R. Davis, S.T. Brookes, and J.M. Blazeby Standards of outcome reporting in surgical oncology: a case study in esophageal cancer Ann. Surg. Oncol. 19 2012 4012 4018
50. G.W. Dittrick, J.M. Weber, R. Shridhar, S. Hoffe, M. Melis, K. Almhanna, J. Barthel, J. McLoughlin, R.C. Karl, and K.L. Meredith Pathologic nonresponders after neoadjuvant chemoradiation for esophageal cancer demonstrate no survival benefit compared with patients treated with primary esophagectomy Ann. Surg. Oncol. 19 2012 1678 1684
51. D. Vallbohmer, A.H. Holscher, S. DeMeester, T. DeMeester, J. Salo, J. Peters, T. Lerut, S.G. Swisher, W. Schroder, E. Bollschweiler, and W. Hofstetter A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer Ann. Surg. 252 2010 744 749
52. Y. Hayashida, K. Honda, Y. Osaka, T. Hara, T. Umaki, A. Tsuchida, T. Aoki, S. Hirohashi, and T. Yamada Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 11 2005 8042 8047
53. J. Wen, B. Zheng, Y. Hu, X. Zhang, H. Yang, Y. Li, C.Y. Zhang, K.J. Luo, X. Zang, Y.F. Li, X.Y. Guan, and J.H. Fu Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP Int. J. Oncol. 36 2010 265 274
54. M. Aichler, M. Elsner, N. Ludyga, A. Feuchtinger, V. Zangen, S.K. Maier, B. Balluff, C. Schone, L. Hierber, H. Braselmann, S. Meding, S. Rauser, H. Zischka, M. Aubele, M. Schmitt, M. Feith, S.M. Hauck, M. Ueffing, R. Langer, B. Kuster, H. Zitzelsberger, H. Hofler, and A.K. Walch Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria J. Pathol. 230 2013 410 419
55. P. Kelly, V. Appleyard, K. Murray, F. Paulin, D. Lamont, L. Baker, S. Suttie, D. Exon, and A. Thompson Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy Br. J. Cancer 103 2010 232 238
56. R. Langer, K. Ott, K. Specht, K. Becker, F. Lordick, M. Burian, K. Herrmann, A. Schrattenholz, M.A. Cahill, M. Schwaiger, H. Hofler, and H.J. Wester Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 14 2008 8279 8287
57. S.G. Maher, D.T. McDowell, B.C. Collins, C. Muldoon, W.M. Gallagher, and J.V. Reynolds Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation Ann. Surg. 254 2011 809 816 (discussion 816-807)
58. H. Jiang, X.H. Wang, X.M. Yu, and Z.G. Zheng Detection and prognostic analysis of serum protein expression in esophageal squamous cell cancer Asian Pac. J. Cancer Prev. 13 2012 1579 1582
59. X.L. Du, H. Hu, D.C. Lin, S.H. Xia, X.M. Shen, Y. Zhang, M.L. Luo, Y.B. Feng, Y. Cai, X. Xu, Y.L. Han, Q.M. Zhan, and M.R. Wang Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma J. Mol. Med. 85 2007 863 875
60. P. Kelly, F. Paulin, D. Lamont, L. Baker, S. Clearly, D. Exon, and A. Thompson Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer Br. J. Cancer 106 2012 955 961
61. H. Igaki, H. Kato, Y. Tachimori, Y. Nakanishi, and T. Shimoda Surgery for clinical T3 carcinomas of the upper thoracic oesophagus and the need for new strategies Br. J. Surg. 92 2005 1235 1240
62. H. Igaki, Y. Tachimori, and H. Kato Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection Ann. Surg. 239 2004 483 490
63. M. Kavallaris, and G.M. Marshall Proteomics and disease: opportunities and challenges Med. J. Aust. 182 2005 575 579
64. L. Vona-Davis, T. Vincent, S. Zulfiqar, B. Jackson, D. Riggs, and D.W. McFadden Proteomic analysis of SEG-1 human Barrett's-associated esophageal adenocarcinoma cells treated with keyhole limpet hemocyanin J. Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract. 8 2004 1018 1023
65. D.W. McFadden, D.R. Riggs, B.J. Jackson, and L. Vona-Davis Keyhole limpet hemocyanin, a novel immune stimulant with promising anticancer activity in Barrett's esophageal adenocarcinoma Am. J. Surg. 186 2003 552 555
66. J.R. Harris, and J. Markl Keyhole limpet hemocyanin: molecular structure of a potent marine immunoactivator Rev. Eur. Urol. 37 Suppl. 3 2000 24 33
67. H. Hu, Y. Ran, Y. Zhang, Z. Zhou, S.J. Harris, L. Yu, L. Sun, J. Pan, J. Liu, J. Lou, and Z. Yang Antibody library-based tumor endothelial cells surface proteomic functional screen reveals migration-stimulating factor as an anti-angiogenic target Mol. Cell. Proteomics 8 2009 816 826
68. J. Tol, M. Koopman, A. Cats, C.J. Rodenburg, G.J. Creemers, J.G. Schrama, F.L. Erdkamp, A.H. Vos, C.J. van Groeningen, H.A. Sinnige, D.J. Richel, E.E. Voest, J.R. Dijkstra, M.E. Vink-Borger, N.F. Antonini, L. Mol, J.H. van Krieken, O. Dalesio, and C.J. Punt Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N. Engl. J. Med. 360 2009 563 572
69. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783 792
70. J. Baselga, I. Bradbury, H. Eidtmann, S. Di Cosimo, E. de Azambuja, C. Aura, H. Gomez, P. Dinh, K. Fauria, V. Van Dooren, G. Aktan, A. Goldhirsch, T.W. Chang, Z. Horvath, M. Coccia-Portugal, J. Domont, L.M. Tseng, G. Kunz, J.H. Sohn, V. Semiglazov, G. Lerzo, M. Palacova, V. Probachai, L. Pusztai, M. Untch, R.D. Gelber, M. Piccart-Gebhart, and A.S.T. Neo Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial Lancet 379 2012 633 640
71. G.D. Demetri, M. von Mehren, C.D. Blanke, A.D. Van den Abbeele, B. Eisenberg, P.J. Roberts, M.C. Heinrich, D.A. Tuveson, S. Singer, M. Janicek, J.A. Fletcher, S.G. Silverman, S.L. Silberman, R. Capdeville, B. Kiese, B. Peng, S. Dimitrijevic, B.J. Druker, C. Corless, C.D. Fletcher, and H. Joensuu Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 347 2002 472 480
72. G.D. Demetri, A.T. van Oosterom, C.R. Garrett, M.E. Blackstein, M.H. Shah, J. Verweij, G. McArthur, I.R. Judson, M.C. Heinrich, J.A. Morgan, J. Desai, C.D. Fletcher, S. George, C.L. Bello, X. Huang, C.M. Baum, and P.G. Casali Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338
73. Y.J. Bang, E. Van Cutsem, A. Feyereislova, H.C. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, J. Hill, M. Lehle, J. Ruschoff, Y.K. Kang, and G.A.T.I. To Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 2010 687 697
74. P.M. Boland, and B. Burtness Esophageal carcinoma: are modern targeted therapies shaking the rock? Curr. Opin. Oncol. 25 2013 417 424
75. P.H. Riegman, K.J. Vissers, J.C. Alers, E. Geelen, W.C. Hop, H.W. Tilanus, and H. van Dekken Genomic alterations in malignant transformation of Barrett's esophagus Cancer Res. 61 2001 3164 3170
76. Y. Song, L. Li, Y. Ou, Z. Gao, E. Li, X. Li, W. Zhang, J. Wang, L. Xu, Y. Zhou, X. Ma, L. Liu, Z. Zhao, X. Huang, J. Fan, L. Dong, G. Chen, L. Ma, J. Yang, L. Chen, M. He, M. Li, X. Zhuang, K. Huang, K. Qiu, G. Yin, G. Guo, Q. Feng, P. Chen, Z. Wu, J. Wu, L. Ma, J. Zhao, L. Luo, M. Fu, B. Xu, B. Chen, Y. Li, T. Tong, M. Wang, Z. Liu, D. Lin, X. Zhang, H. Yang, J. Wang, and Q. Zhan Identification of genomic alterations in oesophageal squamous cell cancer Nature 509 2014 91 95
77. E.P. Xing, G.Y. Yang, L.D. Wang, S.T. Shi, and C.S. Yang Loss of heterozygosity of the Rb gene correlates with pRb protein expression and associates with p53 alteration in human esophageal cancer Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 5 1999 1231 1240
78. L.D. Wang, Y.R. Qin, Z.M. Fan, D. Kwong, X.Y. Guan, G.S. Tsao, J. Sham, J.L. Li, and X.S. Feng Comparative genomic hybridization: comparison between esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-incidence area for both cancers in Henan, northern China Dis. Esophagus 19 2006 459 467
79. K.F. Kwong Molecular biology of esophageal cancer in the genomics era Surg. Clin. North Am. 85 2005 539 553
80. H.B. Chen, K. Pan, M.K. Tang, Y.L. Chui, L. Chen, Z.J. Su, Z.Y. Shen, E.M. Li, W. Xie, and K.K. Lee Comparative proteomic analysis reveals differentially expressed proteins regulated by a potential tumor promoter, BRE, in human esophageal carcinoma cells Biochem. Cell Biol. Biochim. Biol. Cell. 86 2008 302 311
81. J. Zhao, A.C. Chang, C. Li, K.A. Shedden, D.G. Thomas, D.E. Misek, A.P. Manoharan, T.J. Giordano, D.G. Beer, and D.M. Lubman Comparative proteomics analysis of Barrett metaplasia and esophageal adenocarcinoma using two-dimensional liquid mass mapping Mol. Cell. Proteomics 6 2007 987 999
82. J. Breton, M.C. Gage, A.W. Hay, J.N. Keen, C.P. Wild, C. Donnellan, J.B. Findlay, and L.J. Hardie Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma J. Proteome Res. 7 2008 1953 1962
83. Y. Qi, J.F. Chiu, L. Wang, D.L. Kwong, and Q.Y. He Comparative proteomic analysis of esophageal squamous cell carcinoma Proteomics 5 2005 2960 2971
84. Y.J. Qi, Q.Y. He, Y.F. Ma, Y.W. Du, G.C. Liu, Y.J. Li, G.S. Tsao, S.M. Ngai, and J.F. Chiu Proteomic identification of malignant transformation-related proteins in esophageal squamous cell carcinoma J. Cell. Biochem. 104 2008 1625 1635
85. Z. Liu, J.G. Feng, A. Tuersun, T. Liu, H. Liu, Q. Liu, S.T. Zheng, C.G. Huang, G.D. Lv, I. Sheyhidin, and X.M. Lu Proteomic identification of differentially-expressed proteins in esophageal cancer in three ethnic groups in Xinjiang Mol. Biol. Rep. 38 2011 3261 3269